Longitudinal change in quality of life in neurological disorders measures over 3 years in patients with early Parkinson's disease Journal Article uri icon
  • BACKGROUND: The Quality of Life in Neurological Disorders (Neuro-QoL) is a publicly available health-related quality-of-life measurement system. OBJECTIVE: The aim of this study was to evaluate the utility of Neuro-QoL item banks as outcome measures for clinical trials in Parkinson's disease. METHODS: An analysis of Neuro-QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort. RESULTS: Among 310 participants over 3 years, changes in five of eight Neuro-QoL domains were significant (P < 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35-0.39). The largest effect size for change over the year in which levodopa was initiated was -0.19 for lower extremity function-mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group. CONCLUSIONS: More sensitive tools will be required to serve as an outcome measure in early Parkinson's disease.

  • Link to Article
    publication date
  • 2021
  • published in
  • Movement Disorders  Journal
  • Research
  • Drugs and Drug Therapy
  • Measurement
  • Parkinson Disease
  • Quality of Life
  • Additional Document Info
  • 36
  • issue
  • 8